Profile
AMYT ZTS TAK HLN TEVA NBIX
Company Name Amryt Pharma plc Zoetis Inc. Takeda Pharmaceutical Company Limited Haleon plc Teva Pharmaceutical Industries Limited Neurocrine Biosciences, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap - $63.86B $42.85B $42.64B $28.05B $15.29B
Employees 0.29K 13.80K 49.28K 24.56K 37.00K 1.80K
CEO Joseph A. Wiley Kristin C. Peck Christophe Weber Brian James McNamara Richard D. Francis Kyle W. Gano
Ratings
AMYT ZTS TAK HLN TEVA NBIX
Quant Rating Score 3 3 3 3 3 4
Quant Rating Neutral Neutral Neutral Neutral Neutral Buy
Trading
AMYT ZTS TAK HLN TEVA NBIX
Last Close $14.7 $119.56 $13.64 $9.41 $24.46 $154.8
High 52 $14.7 $178.71 $15.52 $11.41 $24.6 $154.8
Low 52 $14.7 $119.56 $12.89 $8.73 $12.82 $87.59
Price vs. 52 Week High 0 % -33.1 % -12.11 % -17.53 % -0.57 % 0 %
Price vs. 52 Week Low 0 % 0 % 5.82 % 7.79 % 90.8 % 76.73 %
Total Return
AMYT ZTS TAK HLN TEVA NBIX
1 Month Return 0 % -16.26 % -5.64 % 6.69 % 21.87 % 12.99 %
3 Month Return 0 % -19.32 % -5.05 % -0.58 % 50.15 % 23.21 %
6 Month Return 0 % -23.31 % -9.43 % -12.59 % 38.98 % 27.23 %
9 Month Return 0 % -30.26 % 0.81 % -1.47 % 45.16 % 26.89 %
YTD Return 0 % -26.62 % 3.02 % -1.36 % 10.98 % 13.41 %
1 Year Return 0 % -31.39 % -1.59 % -1.98 % 39.77 % 24.86 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
AMYT ZTS TAK HLN TEVA NBIX
Dividend Yield Percentage (TTM) - 1.34 % 4.72 % 1.57 % - -
Dividend Paid and Capex Coverage Ration (TTM) 10.05 % 1.89 % 2.01 % 2.01 % 2.78 % 14.57 %
Dividend Per Share (TTM) - 1.93 % 198 % 0.06 % - -
Payout Ratio (TTM) - 32.08 % 226.17 % 27.27 % - -
Growth
AMYT ZTS TAK HLN TEVA NBIX
Asset Growth 45.99 % 0.76 % -9.55 % 14.37 %
Gross Profit Growth 83.12 % -0.19 % 5.47 % 25.65 %
Revenue Growth 21.87 % -0.61 % 4.4 % 24.81 %
Revenue 3 Year 161.4 % 19.01 % 1.52 % 95.79 %
Revenue 5 Year 1707.81 % 33.95 % -5.5 % 172.74 %
Revenue 10 Year - 33.95 % -38.45 % -
EBIT Growth 138.97 % 13.52 % -167.63 % 55.17 %
Net Income Growth 82.62 % 37.46 % -193.2 % 36.68 %
Net Income 3 Yeari Growth Per Share 88.03 % 4.91 % -482.97 % 258.91 %
Net Income 5 Yeari Growth Per Share 74.44 % 122.63 % -58.26 % 741.83 %
Net Income 10 Yeari Growth Per Share -201.65 % 122.63 % -140.46 % 518.75 %
Operating Income Growth 52.38 % 10.52 % -169.98 % 127.38 %
Operating Cash Flow Growth (CFG) -42.24 % 9.57 % -8.85 % 52.71 %
Operating 3 Year CFG 120.18 % 71.6 % 52.26 % 118.72 %
Operating 5 Year CFG 127.9 % 196.04 % 123.59 % 269.64 %
Operating 10 Year CFG 638.54 % 196.04 % -81.66 % 1038.19 %
EPS Growth 86.64 % 33.33 % -190 % 32.81 %
EPS Diluted Growth 87.33 % 33.33 % -190 % 33.2 %
Book Value Per Share 286.78 % -1.63 % -30.36 % 12.91 %
Share Holder 3 Year Equity Growth Per Share 1873.19 % -37.97 % -49 % 77.59 %
Share Holder 5 Year Equity Growth Per Share 12.11 % -40.16 % -62.86 % 271.08 %
Share Holder 10 Year Equity Growth Per Share 17740.42 % -40.16 % -82.6 % 821.72 %
Dividend Per Share Growth - 49.01 % - -
Dividend 3 Year Growth Per Share - -49.79 % - -
Dividend 5 Year Growth Per Share - -49.97 % -100 % -
Dividend 10 Year Growth Per Share - -49.97 % -100 % -
Debt Growth 5.73 % 6.83 % -10.29 % 6.23 %
Free Cash Flow Growth -42.74 % 16.27 % -11.05 % 54.09 %
Updated On 31 Dec 2021 31 Dec 2024 31 Dec 2024 31 Dec 2024
Profitability
AMYT ZTS TAK HLN TEVA NBIX
Gross Profit Margin TTM 52.32 % 70.03 % 52.77 % 61.81 % 49.6 % 98.37 %
Return on Assets TTM -2.32 % 18.04 % 0.98 % 4.78 % -0.39 % 10.03 %
Return on Equity TTM -9 % 53.21 % 1.95 % 9.4 % -2.58 % 15.82 %
Return on Capital Employed TTM -3.46 % 31.67 % 4.8 % 8.34 % 3.16 % 15.17 %
Net Income Per EBT TTM 60.95 % 78.72 % 72.4 % 76.52 % 222.54 % 68.09 %
EBT Per Ebit TTM 137.75 % 94.26 % 33.29 % 88.09 % -7.94 % 114.25 %
EBIT Per Revenue TTM -9.72 % 37.51 % 12.68 % 20.49 % 5.38 % 20.51 %
Cash Flow To Debt Ratio TTM 7.8 % 43.13 % 22.35 % 12.02 % 7.93 % 148.65 %
Receivables Turnover TTM 4.13 6.09 6.59 5.14 4.67 3.69
Payables Turnover TTM 2.58 5.54 5.02 1.18 3.35 0.37
Inventory Turnover TTM 0.92 1.15 1.71 3.72 2.4 0.63
Fixed Asset Turnover TTM 3000.85 % 244.46 % 229.02 % 589.57 % 321.73 % 473.81 %
Asset Turnover TTM 28.41 % 64.82 % 31.99 % 34.62 % 41.43 % 62.89 %
Operating Cash Flow Per Share TTM 0.33 6.58 643.53 0.11 1.21 6.41
Free Cash Flow Per Share TTM 0.3 4.99 521.29 0.1 0.78 5.97
Cash Per Share TTM 239.07 % 322.4 % 22368.59 % 7.46 % 188.4 % 1121.53 %
Operating Cash Flow Sales Ratio TTM 6.98 % 31.21 % 22.48 % 9.32 % 8.36 % 23.74 %
Free Cash Flow Operating Cash Flow Ratio TTM 90.05 % 75.76 % 81.01 % 90.65 % 64.03 % 93.14 %
Cash Flow Coverage Ratios TTM 7.8 % 43.13 % 22.35 % 12.02 % 7.93 % 148.65 %
Price To Free Cash Flows Ratio TTM - 28.78 8.1 34.18 31.29 25.77
Price To Operating Cash Flows Ratio TTM 44.65 21.9 6.51 31.51 20.03 24
Price Cash Flow Ratio TTM 44.65 21.9 6.51 31.51 20.03 24
Income Statement (TTM)
AMYT ZTS TAK HLN TEVA NBIX
Revenue $0.22B $9.26B $4581.55B $11.23B $16.54B $2.36B
Gross Profit $0.12B $6.4B $3001.33B $6.95B $8.06B $2.32B
Gross Profit Ratio 52.32% 69.1% 65.51% 61.85% 48.74% 98.56%
EBITDA $0.03B $3.87B $1210.51B $2.51B $0.78B $0.64B
Net Income $-0.02B $2.49B $107.93B $1.44B $-1.64B $0.34B
EPS Diluted -0.37 5.47 33.62 0.32 -1.45 3.29
Balance Sheet (MRQ)
AMYT ZTS TAK HLN TEVA NBIX
Long Term Debt $0.2B $5.39B $4517.23B $8.62B $16.3B $0.46B
Total Liabilities $0.45B $9.47B $7312.37B $18.09B $33.61B $1.13B
Total Equity $0.34B $4.77B $6935.98B $16.22B $5.72B $2.59B
Total Investments $0B $0.03B $382.4B $0.08B $0B $1.71B
Total Debt $0.2B $6.74B $5066.17B $10.1B $18.08B $0.46B
Total Assets $0.78B $14.24B $14248.34B $34.32B $39.33B $3.72B
Cash Flow Statement (TTM)
AMYT ZTS TAK HLN TEVA NBIX
Net Income $-0.02B $2.5B $107.93B $1.44B $-1.96B $0.34B
Inventory $-0.01B $-0.04B $-34.97B $0.22B $0.17B $-0.02B
Dividends Paid $0B $-0.79B $-302.5B $-0.57B $0B $0B
Operating Cash Flow $0.02B $2.95B $1057.18B $2.3B $1.25B $0.6B
Capital Expenditure $-0B $-0.66B $-200.8B $-0.25B $-0.5B $-0.04B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 4.555
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
AKAN Akanda Corp. 1.315
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 5.705
ALVOW Alvotech 0.78
AMPH Amphastar Pharmaceuticals, Inc. 24.04
AMRX Amneal Pharmaceuticals, Inc. 11.37
ANIP ANI Pharmaceuticals, Inc. 90.49
APUS Apimeds Pharmaceuticals US, Inc 2.2899
AQST Aquestive Therapeutics, Inc. 6.045
ASRT Assertio Holdings, Inc. 0.7609
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 18.7
AYTU Aytu BioPharma, Inc. 2.03
ETFs With Exposure to AMYT
Ticker ETF Name Weight Percentage Price
GWX SPDR S&P International Small Cap ETF 0.04 39.3
Unlock